Skip to search.
 TSX Up 0.33% TSX Ventures Up 1.31%

More On DYAX

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Dyax Corp. (DYAX)

-NasdaqGM
38.41 Up 0.10(0.26%) Jan 21, 4:00PM EST - Nasdaq Real Time Price
Prev Close:N/A
Open:38.41
Bid:N/A
Ask:N/A
1y Target Est:32.58
Beta:1.89139
Next Earnings Date:N/A
Day's Range:N/A - N/A
52wk Range:14.06 - 38.56
Volume:400
Avg Vol (3m):3,617,440
Market Cap:5.65B
P/E (ttm):N/A
EPS (ttm):-0.21
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

Comparison

Symbol% ChgMkt Cap
DYAXUp 0.26%5.65B
BCRXUp 3.77%396.08M

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-15) :N/A
Quarterly EPS Est (Dec-15) :N/A
Mean Recommendation*:3.0
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback